Final-Program-ATS-2023-AP.vp

58

SUNDAY • MAY 21

P29 Patterns of Use in Severe Asthmatic Patients Who Initiate Biologics in Japan / J. Harvey, Collegeville, PA P30 Corticosteroid-sparing Effect of Biologics in Patients With Allergic Bronchopulmonary Aspergillosis/ K.A. Darragh, San Diego, CA P31 Predictive Factors of Favorable Outcome for Mepolizumab Treatment for Eosinophilic Granulomatosis With Polyangiitis: A Case Series/ R. Tsuzuki, Sumida City, Japan P32 A Transcriptomic Signature of Mepolizumab Response in Eosinophilic Granulomatosis With Polyangiitis (EGPA)/ S.H. Baek, Boston, MA P33 Tet1 Regulates Diesel Exhaust Particle (DEP)-Induced Th17 Immune Response/ S. Henson, Davis, CA P34 Cholinergic System in the Exposure of Iron Particles in an Experimental Model of Chronic Allergic Inflammation/ I.C. Tiberio, Sao Paulo, Brazil P35 Biological Effects of Long-term Electronic Cigarette Exposure: Studying the Lungs of Asthmatic Mice/ M.-A. Song, Columbus, OH P36 Mitochondrial Dysfunction Is Enhanced by Electronic Cigarette Exposure in Combination With Established Asthma/ S. Chung, Columbus, OH P37 Fourth Generation E-cigarettes Present Immunosuppressive Properties in Mouse Models of Allergic Asthma/ S. Gaboyan, La Jolla, CA P38 E-cigarette Aerosols Modify the Lung Immune Response in a Murine Model of Allergic Asthma/ S. Paoli, Montreal, Canada P39 Proinflammatory Activation of Lung Macrophages and Altered Bioenergetics Following Chlorine Inhalation in Mice/ R. Malaviya, Piscataway, NJ P40 Efficacy of High-Dose IM Vitamin D on Unplanned Emergency Department Visits for Asthma in Asthmatic Children: Analysis of the Largest Prospective Randomized Trial/ B. Davidson, Everett, WA P41 Triglyceride-Glucose Index and Risk of Asthma Exacerbation/ T.D. Wu, Houston, TX

P13 Residual Dyspnea May Predict Small Airways Dysfunction and Poor Responsiveness to Single-inhaler Triple Therapy in Asthmatic Patients/ K. Ito, Nagoya, Japan P14 The Effect of Long-acting Muscarinic Antagonist on Airway Inflammation Through Leukotrienes/ T. Matsuyama, Kagoshima City, Japan P15 Sputum Tryptase in Patients With Moderate to Severe Asthma/ M. Kjarsgaard, Hamilton, Canada P16 Characteristics of Elderly Severe Asthma: Observations From the Korean Severe Asthma Registry (KoSAR)/ S.-H. Kim, Seoul, Korea, Republic of P17 Predictors of Asthma Exacerbation in a Large Retrospective Cohort and Role of Effect Modification by Female Sex and Race/ M.D. Althoff, Aurora, CO P18 Tmem178 Regulates Calcium Responses in Normal Human Bronchial Epithelial Cells/ A.M. Hernandez Botero, Rochester, MN P19 The Effects of Circulating and Adipocyte-derived Factors From Allergic and Non-allergic Obese Asthmatics on Airway Epithelium Following Bariatric Surgery/ P. Pena Garcia, Burlington, VT P20 Clinical Trial of a Probiotic and Herbal Supplement for Lung and Gut Health/ C.V. Lal, Birmingham, AL P21 Relationship Between Circulating Th2, ILC2, and Follicular Helper T Cells and Airway Obstruction in Bronchial Asthma/ T.K. Tsukuda, Nankoku, Japan P22 Effects of DHEA Treatment on Normal Airway Epithelial Cell Proteins/ N. Marozkina, Indianapolis, IN P23 Characterizing Asthma in Madagascar/ J. Ratomaharo, Athis-Mons, France P24 The MiSTIC Study Design: Medium Strength Triple Therapy Vs High Strength ICS/LABA for Adult Patients With Asthma Uncontrolled on Medium Strength ICS/LABA/ K. Kostikas, Ioannina, Greece P25 Modulating the Level of ICS in Triple ICS/LABA/LAMA FDC: Effect Against Airway Hyperresponsiveness in a Human Ex Vivo Model of Severe Eosinophilic Asthma/ P. Rogliani, Rome, Italy P26 Corticosteroid Changes Mast Cell Receptor Expression and Responses to Asthma-associated Cytokines/ Y. Ohne, Gaithersburg, MD P27 Baseline Characteristics of Patients With Severe Asthma Treated With Mepolizumab: An Interim Analysis of a Multi-country Real-world Cohort/ R.O. Allehebi, Riyadh, Saudi Arabia P28 Demographics and Characteristics of Patients Who Initiate Biologics for Severe Asthma in Japan / J. Harvey, Collegeville, PA

ATS 2023 • Washington, DC